Non-Superiority [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2022-07-26 17:04 (502 d 15:28 ago) – Posting: # 23179
Views: 1,743

Hi Dennis,

❝ ❝ You hope that the complication rates in group A (with medicine) are lower than in group B (without medicine), right?

❝ However, we try to show the complication rates in group B (without medicine) are lower (or not worse or non-inferiority) than in group A (with medicine), …

Essentially you are trying to show that the medicine doesn’t perform better than placebo (assuming the study is double-blind). :-D:blind:

❝ … duo to the medicine is very expensive.

Likely you will face problems with the IEC/IRB:It is the job of the IEC/IRB to make a benefit/risk-assessment for the subjects in the study. To assess a potential socio-econommic advantage for the health system is not in the job description of the members.

❝ Is there any other probelm for the design?

IMHO, ethics.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,823 posts in 4,786 threads, 1,632 registered users;
30 visitors (0 registered, 30 guests [including 10 identified bots]).
Forum time: 07:32 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain.    Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz